bioAffinity Technologies (NASDAQ:BIAF) Issues Earnings Results

bioAffinity Technologies (NASDAQ:BIAF) posted its earnings results on Monday. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.07), Zacks reports. The firm had revenue of $2.20 million for the quarter, compared to analyst estimates of $2.42 million. bioAffinity Technologies had a negative return on equity of 205.09% and a negative net margin of 91.22%. bioAffinity Technologies updated its FY 2025 guidance to EPS.

bioAffinity Technologies Trading Up 319.2 %

NASDAQ BIAF opened at $1.09 on Wednesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.02 and a quick ratio of 1.01. bioAffinity Technologies has a 12 month low of $0.24 and a 12 month high of $3.16. The company has a market capitalization of $16.99 million, a price-to-earnings ratio of -1.33 and a beta of 3.12. The firm’s fifty day moving average price is $0.57 and its 200 day moving average price is $1.06.

Analyst Ratings Changes

Separately, Maxim Group reaffirmed a “hold” rating on shares of bioAffinity Technologies in a research report on Tuesday.

About bioAffinity Technologies

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.